Chambó Renato Caretta, Tsuji Fábio Hissachi, de Oliveira Lima Flávio, Yamamoto Hamilto Akihissa, Nóbrega de Jesus Carlos Márcio
Graduate in Base of Surgery Program, Botucatu Medical School, Sao Paulo State University, Botucatu, Sao Paulo, Brazil.
Department of Pathology, Hospital das Clinicas, Botucatu Medical School, Sao Paulo State University, Botucatu, Sao Paulo, Brazil.
Korean J Urol. 2014 Nov;55(11):725-31. doi: 10.4111/kju.2014.55.11.725. Epub 2014 Nov 4.
We evaluated the utility of 10-, 12-, and 16-core prostate biopsies for detecting prostate cancer (PCa) and correlated the results with prostate-specific antigen (PSA) levels, prostate volumes, Gleason scores, and detection rates of high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical small acinar proliferation (ASAP).
A prospective controlled study was conducted in 354 consecutive patients with various indications for prostate biopsy. Sixteen-core biopsy specimens were obtained from 351 patients. The first 10-core biopsy specimens were obtained bilaterally from the base, middle third, apex, medial, and latero-lateral regions. Afterward, six additional punctures were performed bilaterally in the areas more lateral to the base, middle third, and apex regions, yielding a total of 16-core biopsy specimens. The detection rate of carcinoma in the initial 10-core specimens was compared with that in the 12- and 16-core specimens.
No significant differences in the cancer detection rate were found between the three biopsy protocols. PCa was found in 102 patients (29.06%) using the 10-core protocol, in 99 patients (28.21%) using the 12-core protocol, and in 107 patients (30.48%) using the 16-core protocol (p=0.798). The 10-, 12-, and 16-core protocols were compared with stratified PSA levels, stratified prostate volumes, Gleason scores, and detection rates of HGPIN and ASAP; no significant differences were found.
Cancer positivity with the 10-core protocol was not significantly different from that with the 12- and 16-core protocols, which indicates that the 10-core protocol is acceptable for performing a first biopsy.
我们评估了10针、12针和16针前列腺活检在检测前列腺癌(PCa)方面的效用,并将结果与前列腺特异性抗原(PSA)水平、前列腺体积、Gleason评分以及高级别前列腺上皮内瘤变(HGPIN)和非典型小腺泡增生(ASAP)的检出率相关联。
对354例因各种适应证接受前列腺活检的连续患者进行了一项前瞻性对照研究。351例患者获取了16针活检标本。最初的10针活检标本从双侧的基底部、中间三分之一、尖部、内侧和外侧区域获取。之后,在基底部、中间三分之一和尖部区域外侧的双侧区域再进行6次穿刺,从而获得总共16针活检标本。比较了最初10针标本与12针和16针标本中癌的检出率。
三种活检方案在癌症检出率上未发现显著差异。采用10针方案在102例患者(29.06%)中发现了PCa,采用12针方案在99例患者(28.21%)中发现了PCa,采用16针方案在107例患者(30.48%)中发现了PCa(p = 0.798)。将10针、12针和16针方案与分层的PSA水平、分层的前列腺体积、Gleason评分以及HGPIN和ASAP的检出率进行比较;未发现显著差异。
10针方案的癌症阳性率与12针和16针方案无显著差异,这表明10针方案可用于首次活检。